Life sciences firm Syncona said on Thursday that the third quarter had been a “period of significant activity”, with $674.0m raised by its portfolio and its third successful exit to date.
Syncona posted a 16% uptick in net asset value in the third quarter, boosted by its up to £1.1bn sale of Gyroscope Therapeutics, with net assets reaching £1.33bn by the end of December.
The FTSE 250-listed firm also highlighted that it had announced five “significant financings” in the quarter, raising a total of $674.0m in capital to further support its growing portfolio.
Syncona also noted that its portfolio companies had made “contented clinical and operational progress” throughout the period.
Chief executive Martin Murphy said: “It has been a period of significant activity within the portfolio, with multiple financings, further clinical progress, and our third successful exit to date.
“Many of our companies are approaching clinical data readouts in the next 12 months, and we remain confident in the potential of our portfolio to drive value and deliver transformational treatments to patients.”
As of 0840 GMT, Syncona shares were up 2.72% at 200.50p.
